Kashyap Patel, MD: Misconceptions About Biosimilars

Kashyap Patel, MD, discusses the prevailing misconceptions about biosimilars among oncologists.


That's very interesting question, because the prescribers are still not aware of the rigorous pathway—there’s something called the totality of the evidence that’s undergone in terms of evaluating the molecule. Many prescribers even now think that biosimilars and generics are the same. There’s a significant difference and a significant cost difference in developing a biosimilar, so there are a lot of misconceptions prevailing among my colleagues as well as many prescribers. As a chairman of the biosimilars committee at the [Community Oncology Alliance, COA], we’re trying to help address the knowledge gap and the needs assessment in the biosimilars market.

Related Videos
Christine Baeder Smiling
Michael Kleinrock
Ian Henshaw
Ian Henshaw
Ryan Haumschild, PharmD
John Gabrielson
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumdschild, PharmD
banner for the ophthalmology linkedin live event sponsored by the samsung bioepis in partnership with the center for biosimilars
Ryan Haumschild, PharmD
Related Content
© 2023 MJH Life Sciences

All rights reserved.